The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC): Regional Southern Italy experience.
V. Adamo
No relevant relationships to disclose
G. R. R. Ricciardi
No relevant relationships to disclose
B. Adamo
No relevant relationships to disclose
B. Agostara
No relevant relationships to disclose
M. Caruso
No relevant relationships to disclose
V. Gebbia
No relevant relationships to disclose
N. Gebbia
No relevant relationships to disclose
G. Lavenia
No relevant relationships to disclose
G. L. Banna
No relevant relationships to disclose
A. Mafodda
No relevant relationships to disclose
R. Rossello
No relevant relationships to disclose
A. Butera
No relevant relationships to disclose
S. Spada
No relevant relationships to disclose
N. Borsellino
No relevant relationships to disclose
A. Mangiameli
No relevant relationships to disclose
M. Campiglio
No relevant relationships to disclose
G. Tuccari
No relevant relationships to disclose